Navigation Links
GeoVax Phase 2a Clinical Trial Completes Enrollment
Date:10/3/2011

orm of the HIV envelope protein can elicit neutralizing Ab for tier 2 viruses."

"The completion of enrollment for our phase 2a trial is an important milestone," said Robert  McNally, Ph.D., GeoVax's President and CEO. "We now look forward to completion of the inoculations and the unblinding of safety and immunogenicity results for the entire trial."

Patient enrollment for HVTN 205 was conducted at 11 clinical sites in North America and two sites in South America.

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of Phase 2 testing and the extension of clinical testing to include a granulocyte macrophage-colony stimulating factor (GM-CSF) adjuvanted version of the vaccine.  GeoVax is also enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.

About the HVTN

The HIV Vaccine Trials Network (HVTN) is the largest worldwide clinical trials network dedicated to the d
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
2. GeoVax Labs, Inc. Announces Second Quarter Financial Results
3. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
4. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
5. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
6. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
7. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
8. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
9. GeoVax Labs Engages The Investor Relations Group
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
11. GeoVax Labs, Inc. Plans Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Pete Rose, baseball,s all-time hits leader, is ... pain reliever Myoflex, Ducere Pharma has announced. "Pete,s ... excited to have him on board with Myoflex," said Ducere ... a legendary player who is known across all generations. The ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... FRANCISCO, Nov. 8, 2011 InspireMD, Inc. (OTC ... device company focusing on the development and commercialization ... that new clinical findings including a summary of ... doctors at numerous lectures during the Transcatheter Cardiovascular ...
... SILVER SPRING, Md., Nov. 8, 2011 Many ... their medical conditions at home.  These conditions include ... disorders, migraines and cancer. Sharps are also used ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO )   ...
Cached Medicine Technology:InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 2InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 3InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 4FDA CONSUMER HEALTH INFORMATION - Improperly Discarded 'Sharps' Can Be Dangerous 2
(Date:1/22/2015)... 2015 Angelweddingdress is a famous wedding dress ... customers to follow it on Facebook, Twitter, and Pinterest. The ... gift. Angelweddingdress draws a lottery every week. , Moreover, the ... 28, 2015. Click Angelweddingdress homepage for more information. ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and David ... Show to bestow a Juvent Sports Achievement award upon ... McKitrick. The award commemorated and congratulated McKitrick for her ... won her first amateur tournament in 1979 and most ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... it comes to pain, the two competing schools of thought ... in your body". A new study led by University of ... the two. Depression and pain often co-occur, but ... To examine the interaction between depression and pain, Dr. Chantal ...
... The prevalence of mild sleep-disordered breathing in young ... will be presented Monday, June 7, 2010, in San ... of the Associated Professional Sleep Societies LLC. Results ... mild sleep-disordered breathing in elementary-school children increased steadily from ...
... CITYFindings of a clinical trial reported at SNM,s 57th ... could improve diagnosis of recurrent prostate cancer and determine ... "Despite definitive treatment, about 30 percent of ... the division of nuclear medicine and molecular imaging and ...
... SALT LAKE CITYChester A. Mathis, Ph.D., director of the ... University of Pittsburgh, has been named as this year,s ... was presented the award by SNMa leading molecular imaging ... 5𔃇, in Salt Lake City, Utah. The Paul C. ...
... treatment for melanoma that has spread to the liver ... liver,s blood vessels, according to a study sponsored by ... led by James F. Pingpank, M.D., associate professor of ... oncologist with UPMC Cancer Centers. The results will be ...
... leukemia patients responded to Sprycel and Tasigna than Gleevec ... drugs, dasatinib (Sprycel) and nilotinib (Tasigna), appear better than ... myeloid leukemia and should be considered as first-line treatments, ... change clinical practice, are to be presented Saturday at ...
Cached Medicine News:Health News:Study finds a seasonal variance in sleep-disordered breathing in young children 2Health News:Molecular imaging detects recurrent prostate cancer 2Health News:Chester A. Mathis receives SNM's 2010 Aebersold Award 2Health News:Chester A. Mathis receives SNM's 2010 Aebersold Award 3Health News:New treatment method safe, effective for advanced melanoma patients 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 3Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 4
With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information....
... OS) makes the patient appointment, the charge ... the MedPlexus System accessible through a ... have access to data that was previously ... appointment schedules, create super bills and more. ...
MD Coder Charge Capture Pocket PC Edition is a charge capture tool. We have integrated the feedback from hospitals and physicians. MD Coder Charge Capture supports both the Palm OS and Pocket PC plat...
... Zapcode follows the HCFA Evaluation and Management ... the history and exam information, it calculates the ... You can also see the effect of changing ... all of the information you entered to create ...
Medicine Products: